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ABSTRACT The cellular effects of numerous hormones
and neurotransmitters, including the vasoactive agents angio-
tensin II (Angil) and [Args]vasopressin, are mediated in part by
protein-serine/threonine kinases activated by increase of cyto-
solic Ca2+ concentration. In this study, we have tested the ability
of Ca2+-mobilizing agents to activate cellular tyrosine kinases.
Treatment of intact GN4 liver epithelial cells with Angl rapidly
('15 sec) increased tyrosine kinase activity measured either in
unfractionated cell lysates or in anti-phosphotyrosine immune
complexes from detergent-solubilized cells. Increased phosphor-
ylation of the exogenous substrate poly(GlusiTyr2D) (3- to 4-fold
over control) by immunoprecipitated kinases closely paralleled
the time- and dose-dependence of the appearance of tyrosine
phosphoproteins in intact cells. This effect of AnglI was mim-
icked by thapsigargin, a Ca2+-elevating tumor promoter. The
ability of Angl, but not epidermal growth factor, to increase
tyrosine kinase activity was blocked in cells loaded with the Ca2'
chelator bis-(O-aminophenoxy)-ethane-NNN',N'-tetraacetic
acid. Dephosphorylation of immunoprecipitated proteins by
tyrosine phosphatase treatment was accompanied by a 60-70%
loss in in vitro kinase activity, suggesting that the Angl-sensitive
kinase(s) are activated by phosphorylation in intact cells. These
findings demonstrate a link between two widely occurring
signaling pathways, the tyrosine kinases and the Ca2+ second-
messenger system, and suggest the possible involvement of
Ca2+-activated tyrosine kinases in the endocrine actions ofAngIl
and [Argglvasopressin.
Reversible phosphorylation of proteins on tyrosine residues
is a regulatory mechanism frequently associated with cell
growth and mitosis. The receptors for several peptide growth
factors, including epidermal growth factor (EGF), platelet-
derived growth factor, and insulin-like growth factor I, as
well as the transforming proteins of several oncogenes (e.g.,
src, abl) contain tyrosine kinase domains essential for
growth-promoting activity (1, 2). In comparison to the re-
ceptor kinases, which are known to be activated by ligand
binding, the pathways regulating nonreceptor tyrosine ki-
nases are poorly understood. Likewise, the biological func-
tion of nonreceptor tyrosine kinases in both proliferating and
nonproliferating cells is unclear. However, the abundance of
tyrosine kinase activity in terminally differentiated cells such
as platelets (3) and neurons (4) has suggested non-growth-
related roles for tyrosine phosphorylation in processes as
diverse as secretion and neural plasticity.
Studies in our laboratory have shown that treatment ofWB
rat liver epithelial cells with angiotensin II (AngII),
[Arg8]vasopressin, or epinephrine rapidly increases cellular
protein-phosphotyrosine [Tyr(P)] content in a Ca2+-
dependent, protein kinase C-independent fashion (5). These
agents are members of a large class of hormones and neuro-
transmitters that increase cytosolic Ca2+ and diacylglycerol
levels by activating receptors linked to phospholipase C via
a GTP-binding protein (6). In turn, cellular effects of such
hormones are believed principally to involve serine/
threonine protein kinases, notably the Ca2+/calmodulin-
dependent kinases and protein kinase C. However, our
findings have suggested the existence of an additional path-
way by which intracellular Ca2+ acts-modulation of the
tyrosine-phosphorylation states of specific proteins (5). Al-
though Ca2I-activated tyrosine phosphorylation recently has
been reported in several other cell types, including vascular
smooth muscle (7), neutrophils (8), platelets (9, 10), and
hippocampal cells (11), the mechanism of this response
remains to be elucidated. In the present studies, we have
examined the hypothesis that mobilization of Ca2+ increases
steady-state levels of tyrosine-phosphorylated proteins by
activating tyrosine kinases.
EXPERIMENTAL PROCEDURES
Anti-Tyr(P) Immunoprecipitation. Confluent cultures of
GN4 cells in 60-mm dishes were washed once with serum-
free medium and were stimulated with various agents at 370C
for the times indicated. Cells were lysed with ice-cold lysis
buffer [20 mM Hepes (pH 7.3) containing 500 mM NaCl, 50
mM NaF, 5 mM EDTA, 1 mM Na3VO4, 1% Triton X-100,
10% (vol/vol) glycerol, and 10 ,ug of phenylmethylsulfonyl
fluoride, 20 ,ug of leupeptin, and 100 kallikrein inhibitor units
of aprotinin per ml], and lysates were clarified by centrifu-
gation at 14,000 x g for 15 min at 4°C. Tyrosine-phosphor-
ylated proteins were precipitated by incubation with mono-
clonal anti-Tyr(P) antibody [qualitatively similar results were
obtained with antibodies PY20 (1 ug per 500 pg of total
protein; ICN) and PT-66 (1 ,ul per 500 ,ug; Sigma)], 5 Pg of
rabbit anti-mouse IgG, and 10 .ul of pansorbin (Calbiochem)
for 3 hr at 4°C. Immune complexes were collected by
centrifugation at 14,000 x g for 3 min at 4°C, were washed
once with lysis buffer and twice with 2-fold-concentrated
tyrosine kinase assay buffer (100 mM sodium Hepes, pH
7.6/60 mM MgCl2/2 mM MnCl2/0.2 mM Na3VO4/0.2%
Nonidet P-40), and then were resuspended with 70 Al of this
buffer. In some experiments, an aliquot (10-20 pul) of the
washed immune complex was removed for anti-Tyr(P) im-
munoblotting after SDS/PAGE on 8% gels as described (12).
Efficient anti-Tyr(P) recovery of tyrosine phosphoproteins
and kinase activity required high NaCl concentration (500
mM) in the cell lysis buffer. We postulate that Tyr(P) residues
are dissociated from endogenous binding domains [e.g.,
src-homology domains (13)] at high ionic strength and
thereby are made accessible for immunoprecipitation, since
association of several WB cell tyrosine phosphoproteins with
phospholipase C-y1 is reversed at high ionic strength (14).
Abbreviations: EGF, epidermal growth factor; AngII, angiotensin H;
Tyr(P), phosphotyrosine; BAPTA, bis-(O-aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid.
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Immune Complex Tyrosine Kinase Assay. Routinely, 10-1.l
aliquots of immune complex suspension were preincubated
for 5 min at 40C with 160 gg of the synthetic tyrosine kinase
substrate poly(Glu8OTyr20) (15) or the control substrate poly-
(Glu). Reactions (80-pl total reaction volume) were initiated
by addition of 5 gM [y-32P]ATP (5 uCi per reaction; 1 Ci =
37 GBq). After 4 min at 25TC, 50 gl of the reaction mix was
spotted onto Whatman 3MM paper. The papers were washed
with trichloroacetic acid, air-dried, and assayed by liquid
scintillation for acid-insoluble 32p (16). Tyrosine kinase ac-
tivity was defined as 32p incorporation in cpm occurring in the
presence of poly(Glu80Tyr20) minus that occurring in the
presence of poly(Glu). This procedure allows estimation of
poly(Glu80Tyr20) phosphorylation above the background of
endogenous protein phosphorylation. The rates of tyrosine
phosphorylation so measured were linear for at least 15 min
and were proportional to the amount of cell lysate used for
immunoprecipitation.
Intracellular Ca2+ Measurements. GN4 cells grown on
22-mm diameter glass coverslips were incubated with 5 ,uM
fura-2/AM (acetoxymethyl ester) for 25 min at 37°C and then
were washed and incubated in a balanced salt solution (10
mM Hepes/138 mM NaCl/5.3 mM KCl/1.3 mM CaCl2/0.8
mM MgCl2/0.35 mM Na2HP04/0.44 mM KH2PO4/5.6 mM
glucose, pH 7.3) for 5 min prior to addition of AngIl.
Microscopic fields containing 50-60 cells were monitored for
fluorescence emission at 505 nm under excitation at 340 and
380 nm by using a SPEX analytical system (17).
Autophosphorylation and Phosphoamino Acid Analysis. Ali-
quots of washed immune complex suspensions were incu-
bated for 10 min at 25°C in the presence of 25 ,uCi of
[y-32P]ATP without poly(Glu8OTyr20) and then were subjected
to SDS/PAGE, electrophoretic transfer to Immobilon mem-
branes (Millipore), and autoradiography. Regions of the
membrane containing the 32P-labeled species of interest were
excised and subjected to acid hydrolysis, two-dimensional
electrophoresis, and autoradiography (18). 32P-labeled phos-
phoserine, Ser(32P); phosphothreonine, Thr(32P); and
Tyr(32P) were located by comigration with ninhydrin-stained
standards.
RESULTS AND DISCUSSION
In a recent report, we showed that AngII treatment ofWB rat
liver epithelial cells increases the phosphorylation states of
several proteins in a Ca2+-dependent fashion (5). In the
present studies, we have evaluated the effects of Ca2+-
mobilizing agents on cellular tyrosine kinases, by measuring
tyrosine kinase activities in cell-free preparations. In initial
experiments, unfractionated lysates from control and AngII-
treated cells were assayed by measuring incorporation of 32p
into an acid-insoluble synthetic tyrosine kinase substrate,
poly(Glu80Tyr20). However, high background activities of
serine/threonine kinases toward endogenous lysate proteins
prevented reliable assessment of relative tyrosine kinase
activities. We have circumvented this problem by preparing
anti-Tyr(P) immunoprecipitates from AngIl-treated cells
prior to assay with poly(Glu80Tyr20). This procedure was
designed to detect activated tyrosine kinases which, if similar
to a number of known receptor and nonreceptor tyrosine
kinases (1, 2, 19-23), autophosphorylate when activated.
Anti-Tyr(P) immunoblotting of anti-Tyr(P) immunoprecipi-
tates from control and treated cells revealed that recovery of
tyrosine-phosphorylated proteins was specific and efficient:
no tyrosine phosphoproteins were precipitated when nonim-
mune mouse IgG was substituted for monoclonal anti-Tyr(P)
(e.g., see Fig. 4 Left) or when specific immunoprecipitation
was blocked by 1 mM phenylphosphate, and no Tyr(P)-
containing proteins were detectable in supernatants after one
round of immunoprecipitation (not shown).
Initially, studies of tyrosine kinase activation were con-
ducted with the WB and GN4 cell lines. The latter was
derived previously from WB cells by serial treatment with
N-methyl-N'-nitro-N-nitrosoguanidine (24). GN4 cells exhib-
ited an -3-fold greater AngII-stimulated increase in endog-
enous protein-tyrosine phosphorylation compared with WB
cells, whereas responses to EGF were of similar magnitude
in the two lines (Fig. 1 Upper). EGF treatment of the two cell
types stimulated similar (-3-fold) increases in tyrosine ki-
nase activity measured by using anti-Tyr(P) immunoprecip-
itates of cell lysates (Fig. 1 Lower). As anticipated, the
activity recovered from EGF-treated cells is due in part to the
presence of activated EGF receptors, based on the appear-
ance of a 170-kDa tyrosine-phosphorylated species in anti-
Tyr(P) immunoprecipitates that is recognized by anti-EGF
receptor antibodies. AngII treatment of both WB and GN4
cells also stimulated increases in immune complex tyrosine
kinase activity (Fig. 1 Lower), with GN4 cells again being
more responsive than WB cells (340% vs. 160o of control
activity, respectively). These results are consistent with a
link between endogenous protein-tyrosine phosphorylation
and kinase activation in response to AngII and prompted us
to use GN4 cells in subsequent studies.
The effects of AngII treatment on tyrosine kinase activity
were rapid (.15 sec) and transient (maximal at 45-60 sec;
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FIG. 1. Increased tyrosine phosphorylation and tyrosine kinase
activity in WB and GN4 cells. Confluent cultures of WB and GN4
cells were treated with EGF at 300 ng/ml for 1 min or with 1 ,uM
AngII for 45 sec forWB cells or 1 min for GN4 cells under conditions
that allowed maximal increase of both tyrosine phosphorylation and
recovered kinase activity compared with control cells (lanes C).
(Upper) WB and GN4 cells treated as indicated were lysed with
radioimmunoprecipitation assay (RIPA) buffer and were subjected to
anti-Tyr(P) immunoblotting as described (12). (Lower) Tyrosine
kinase activity toward poly(Glu8OTyr20) was assayed in anti-Tyr(P)
immune complexes derived from WB or GN4 cells as described in
text. The results shown (mean + SEM from the number of experi-
ments indicated in parentheses) are expressed as a percentage of the
control (untreated) tyrosine kinase activity.
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Fig. 2). This increase corresponded temporally to the ap-
pearance of endogenous tyrosine-phosphorylated proteins in
intact GN4 cells (not shown). Both responses to AngII were
dose-dependent, with half-maximal effects occurring at -1
nM. No measurable tyrosine kinase activity was immuno-
precipitated in the presence of phenylphosphate or when
anti-Tyr(P) antibodies were replaced by nonimmune IgG.
To validate the results obtained with immunoprecipitates,
we performed [32P]ATP-autokinase assays using unfraction-
ated cell lysates prepared in kinase assay buffer containing
1% Triton X-100. Anti-Tyr(P) immunoprecipitation of the in
vitro phosphorylated lysates, followed by SDS/PAGE and
phosphoamino acid analysis, revealed an :2-fold increase in
total protein-associated Tyr(32P) content in lysates of AngII-
treated cells compared to controls. These results indicate that
relative tyrosine kinase activities measured in anti-Tyr(P)
immune complexes are representative ofthose in cell lysates.
AngIl is known to rapidly increase intracellular Ca2+ and
diacylglycerol concentrations in target cells (5, 25-27). We
have shown that Ca2+ mobilization but not protein kinase C
activation is necessary for elevation of tyrosine phosphory-
lation in response to AngIl (5). To evaluate the role of Ca2+
in AngII-stimulated tyrosine kinase activation, GN4 cells
were loaded with the Ca2+ chelator bis-(O-aminophenoxy)-
ethane-N,N,N',N'-tetraacetic acid (BAPTA) (28) prior to
AngII treatment. In BAPTA-loaded cells, the AngII-
stimulated increase in cytosolic Ca2+, measured by fura-2
fluorescence, was reduced by >90%o (Fig. 3 Upper). BAPTA
pretreatment also completely abolished the AngII-stimulated
increase in immune complex tyrosine kinase activity but had
little effect on immune complex tyrosine kinase activity from
EGF-treated cells (Fig. 3 Lower). This lack of an effect of
BAPTA on EGF receptor kinase activity is consonant with
the known Ca2+-independence of this enzyme (29) and indi-
cates the absence of toxic or nonspecific effects of BAPTA
on GN4 cells in this context. To further evaluate the involve-
ment of Ca2+ in tyrosine kinase activation, GN4 cells were
treated with the tumor promoter thapsigargin, which pro-
motes Ca2+ release from endoplasmic reticulum (30). Treat-
ment with 2 ,uM thapsigargin for 5 min increased immune
complex tyrosine kinase activity to 245 ± 38% of vehicle
controls (mean ± SEM, n = 5 separate experiments). In
contrast, treatment with the protein kinase C activator phor-
bol myristate acetate at 300 nM for 10 min had no significant
effect on recovery of tyrosine kinase activity.
The successful recovery of tyrosine kinase activity from
AngII-treated cells by anti-Tyr(P) immunoprecipitation sug-
gests that this activity may reside in one or more of the
tyrosine-phosphorylated species detected by immunoblotting
(Fig. 1). To investigate the possible presence of autophos-
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FIG. 2. Time-course ofAnglI-stimulated tyrosine kinase activity.
Tyrosine kinase activity was assayed in anti-Tyr(P) immune com-
plexes derived from GN4 cells treated with AngII for the times
indicated. The results shown (mean + SEM from three experiments)
are expressed as a percentage of control (untreated) tyrosine kinase
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FIG. 3. Inhibition of Ca2+ mobilization and tyrosine kinase
activation by BAPTA. (Upper) Fura-2 fluorescence was monitored
in GN4 cells pretreated with either vehicle (0.1% dimethylsulfoxide)
or 25 jLM BAPTA acetoxymethyl ester (BAPTA/AM) for 15 min.
Cells were stimulated with 1 ,uM AngII at the times indicated by the
arrows. Ca2+ concentration is reported as the 340/380-nm fluores-
cence ratio. (Lower) Tyrosine kinase activity was assayed in anti-
Tyr(P) immune complexes derived from GN4 cells that had been
pretreated with BAPTA/AM or vehicle as in Upper and then treated
for 1 min with EGF at 300 ng/ml or 1 AM AngII. The results shown
represent mean ± SEM from three experiments.
incubated with ['y32P]ATP in the absence of poly(Glu8O-
Tyr20), and phosphorylated proteins were detected by auto-
radiography after SDS/PAGE. The resulting patterns of in
vitro phosphorylation strongly resembled those detected by
anti-Tyr(P) immunoblotting of immune complexes, with pro-
tein species of apparent molecular masses 66 (p66), 75/78
(p75/78), 93 (p93), and 115/125 (p115/125) kDa becoming
phosphorylated (Fig. 4 Left). Phosphoamino acid analysis of
the p66, p75/78, and p115/125 species revealed that in vitro
phosphorylation was detectable only on tyrosine (Fig. 4
Right). Treatment ofGN4 cells with 1 ,uM [Arg8]vasopressin
for 1 min produced a similar pattern of activated autophos-
phorylation (not shown). These results suggest that the
proteins recovered by anti-Tyr(P) immunoprecipitation are
subject to further phosphorylation in vitro, either as auto-
phosphorylating kinases or as kinase substrates. Whether the
proteins phosphorylated in vitro are identical to those phos-
phorylated in intact cells and which, if any, of the detectable
species contain kinase activity remain to be determined.
Taken together, the present findings support the hypoth-
esis that AngII activates a Ca2+-dependent process, resulting
in increase of tyrosine kinase activity. The appearance of
tyrosine-phosphorylated endogenous proteins in response to
AngII closely paralleled changes in immune complex tyrosine
kinase activity in terms of time- and dose-dependence and
Ca2+ requirements. We have considered several alternative
explanations for our results. It is conceivable, for example,
that an apparent increased recovery of tyrosine kinase ac-
tivity by immunoprecipitation might reflect a decreased level
oftyrosine phosphatase activity recovered from treated cells.
However, anti-Tyr(P) immunoprecipitates from control or
AngII-treated cells contained no detectable tyrosine phos-
phatase activity when heat-denatured 32P-autophosphory-
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FIG. 4. In vitro phosphorylation of endogenous proteins in anti-Tyr(P) immune complexes. (Left) Lysates from control GN4 cells (lanes C)
or from GN4 cells treated with 1 jAM AngIH for 1 min were immunoprecipitated with nonimmune mouse IgG (lanes NI) or monoclonal anti-Tyr(P)
(lanes PY). Aliquots (25 p4) of the immune complex suspension were subjected to SDS/PAGE, electrophoretic transfer to nitrocellulose, and
anti-Tyr(P) immunoblotting (lanes 1-4). For autokinase assay, 25-p4 aliquots of the same suspensions were incubated for 10 min at 250C in the
presence of 25 ACi of [y-32P]ATP and then subjected to SDS/PAGE, electrophoretic transfer to Immobilon (Millipore), and autoradiography
(lanes 5-8). (Right) The regions of Immobilon membrane containing the 32P-labeled p66/75/78, and p115/125 species from anti-Tyr(P)
immunoprecipitates of control (Left, lane 6) or AngII-treated (Left, lane 8) cells were excised and subjected to phosphoamino acid analysis.
Locations ofninhydrin-stained phosphoserine (PS), phosphothreonine (PT), and Tyr(P) (PY) standards are indicated. The hydrolyzed p66/75/78
regions shown yielded 13 and 176 cpm of Tyr(32P) (above blank) from control and AngII-treated cells, respectively, while the corresponding
p115/125 regions yielded 25 and 245 cpm.
lated rat liver EGF receptor was used as a substrate. Fur-
thermore, there was no detectable loss of Tyr(P) from
immunoprecipitated proteins when either immune complexes
or eluted phosphoproteins were incubated for up to 30 min in
the presence of all kinase assay components except ATP.
Therefore, it is unlikely that decreased recovery of phospha-
tase activity rather than increased kinase activity can account
for the effects ofAngII treatment on phosphorylation rates in
the immune complex assay.
Secondly, it might be argued that the presence of precip-
itating antibodies in the immune complex assay could arti-
factually alter tyrosine kinase activities. To test this possi-
bility, Tyr(P) proteins were specifically eluted from immune
complexes prior to kinase assay. Washed anti-Tyr(P) immu-
noprecipitates from control and AngII-treated GN4 cells
were resuspended in 2-fold concentrated assay buffer con-
taining 1 mM p-nitrophenyl phosphate. After 30 min at 4°C,
eluted proteins were separated from the immune complex by
centrifugation for 5 min at 14,000 x g and 4°C. p-Nitrophenyl
phosphate eluted >95% of the detectable Tyr(P) proteins
from anti-Tyr(P) antibodies. There was no detectable change
in tyrosine kinase activity in eluates compared with non-
eluted immune complexes assayed either by autophospho-
rylation or poly(Glu81'yr20) phosphorylation (not shown),
indicating that the precipitating antibodies do not influence
the activity of the recovered kinases.
Finally, the possibility exists that increased recovery of
tyrosine kinase activity merely reflects an increase in the pool
of phosphorylated tyrosine kinase molecules by a process
that is not a consequence of kinase activation. To assess the
relationship between the phosphorylation state of recovered
kinases and their activities, Tyr(P) proteins eluted from
immune complexes were dephosphorylated by treatment
with recombinant human T-cell tyrosine phosphatase (37-
kDa form) (31). Tyrosine phosphatase treatment removed
virtually all detectable tyrosine phosphate from eluted pro-
teins (Fig. 5 Left). This dephosphorylation was accompanied
by a 60-70%o loss in the kinase activity measured subse-
quently with poly(Glu8OTyr20) in the presence of vanadate
(Fig. 5 Right). The ability of vanadate to inhibit the T-cell
phosphatase was confirmed by the complete blockade of
protein dephosphorylation when phosphatase incubations
contained vanadate (Fig. 5 Left); inhibition of dephosphor-
ylation was accompanied by retention of kinase activity (Fig.
5 Right). Therefore, we conclude that the loss of kinase
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FIG. 5. Loss of tyrosine kinase activity after tyrosine dephosphorylation. Anti-Tyr(P) immunoprecipitates from control and AngII-treated
GN4 cells were washed twice with 25 mM imidazole (pH 7.2) and eluted from anti-Tyr(P) by incubation with this buffer containing 0.05% Triton
X-100, 0.1% 2-mercaptoethanol, and 1 mM p-nitrophenyl phosphate. Eluted proteins were incubated with 1 mM sodium orthovanadate (lanes
Van.), recombinant T-cell tyrosine phosphatase (lanes PTPase; -1 ng/pg of total cell protein), or vanadate plus phosphatase for 3 min at 250C.
Vanadate (1 mM) was then added to phosphatase-only samples, and aliquots of all samples were subjected to anti-Tyr(P) immunoblotting (Left)
or in vitro kinase assay with poly(GluwJTyr2O) (Right).
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tated proteins rather than from residual activity of T-cell
phosphatase toward poly(Glu8Tyr20) or from other contam-
inating hydrolases. This finding indicates that the tyrosine
phosphorylation of tyrosine kinases (or persistently associ-
ated regulatory proteins) recovered from AngII-treated cells
both reflects and dictates increased kinase activity. Further-
more, these results validate our rationale for seeking evi-
dence of kinase activation that occurred in intact cells by
examining anti-Tyr(P) immunoprecipitates.
The sensitivity of AngII-stimulated tyrosine kinase activ-
ities to tyrosine dephosphorylation strongly suggests that
phosphorylation of these kinases is a major factor in their
mechanism of activation. It remains to be established
whether this increased kinase phosphorylation is due to
autophosphorylation or activation of an intermediating ki-
nase. In either event, these putative enzymes could be
directly regulated in a positive manner by increased intra-
cellular Ca2+, as suggested for a reported Ca2+/calmodulin-
activated tyrosine kinase (32) or a soybean serine/threonine
kinase that contains a Ca2+-binding domain (33). Alterna-
tively, modulation oftyrosine phosphatase activity may be an
event more proximal to AngII-stimulated Ca2+ mobilization.
Thus, Ca2+ might maintain one or more tyrosine kinases in an
activated (i.e., tyrosine-phosphorylated) state by inhibiting
their dephosphorylation. Such a mechanism would require
the presence of a basal level of phosphorylating (i.e., kinase-
activating) activity in untreated cells, a criterion that is
satisfied by the recovery of measurable phosphatase-
sensitive tyrosine kinase activity from control cells (Fig. 5).
A tyrosine phosphatase that is inhibited by Ca2+ has been
isolated from bovine brain (34), and Ca2+-mediated inhibition
of the leukocyte tyrosine phosphatase CD45 has been re-
ported (35), but the involvement of an analogous mechanism
in WB or GN4 cells is untested.
The identity of the kinase(s) involved in AngII-stimulated
increases in tyrosine phosphorylation remains unknown. We
must consider as candidates known tyrosine kinases, such as
the insulin receptor (21, 22) and members of the src family
(23, 36, 37), whose activity appears to be regulated positively
by autophosphorylation. We have found that immunoprecip-
itation with antibodies recognizing the common C-terminal
peptide of src-related kinases did not decrease AngII-
stimulated tyrosine kinase activity subsequently recovered
with anti-Tyr(P) (unpublished data), suggesting that the Ang-
II-responsive enzymes are not members of this kinase family.
In addition, preliminary subcellular fractionation studies
indicate that at least part of the AngII-stimulated activity is
cytosolic, suggesting that this activity cannot wholly be
attributed to transmembrane kinases such as the insulin
receptor. Ongoing studies seek to identify the AngII-
responsive kinases and to determine whether their mode of
activation is common to many cell types. Given the wide-
spread occurrence of receptor-mediated Ca2+ mobilization,
we anticipate that Ca2+-dependent tyrosine kinase activation
may prove to be of fundamental interest, and elucidation of
its mechanism may provide new insights into both the acute
and growth-regulating actions of Ca2+-mobilizing hormones
and neurotransmitters.
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